Bicara Therapeutics Inc. - Common Stock (NQ:BCAX)

Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

September 03, 2026

Performance

52-Week Range 40.8% below 52-week high

18.35

13.7052W Low 30.9952W High

1 Week 1.6% below 1-week high

16.601W Low 18.641W High

Bicara Therapeutics Inc. - Common Stock (BCAX) traded between $13.70 and $30.99 over the past 52 weeks and last traded at $18.35, 40.8% below its 52-week high. Over the past week it ranged between $16.60 and $18.64.

Past 12 Months

+5.8%

-16.6%

-34.8%

-20.6%

+12.0%

+12.9%

1W +$1.01

1M -$3.66

3M -$9.80

6M -$4.76

YTD +$1.97

1Y +$2.09

BCAX was +12.9% over the past year, -20.6% over six months, +12.0% year to date, +5.8% in the last week.

12 Months vs Market

BCAX

+12.9%

DIA

+12.3%

SPY

+14.6%

QQQ

+17.3%

IWM

+11.1%

Over the past 12 months BCAX returned +12.9% versus DIA (Dow) +12.3%, SPY (S&P 500) +14.6%, QQQ (Nasdaq 100) +17.3% and IWM (Russell 2000) +11.1%.

Volume & Liquidity 0.73× 3-mo avg

Today 493,418 3-mo avg 671.4K

853.9K

835.2K

671.4K

675.9K

YTD

624.0K

642.1K

BCAX most recently traded 493,418 shares against a 3-month average daily volume of 671.4K.

More News

Bicara Therapeutics (BCAX) Q2 2026 Earnings Call Transcript ↗

August 18, 2026

Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

August 14, 2026

Bicara Therapeutics (NASDAQ:BCAX) Q1 2026 Results Highlight Clinical Progress as EPS Misses Estimates ↗

May 11, 2026

Via Chartmill

Bicara Therapeutics Q2 Earnings Call Highlights ↗

August 11, 2026

Bicara Therapeutics Reports Second Quarter 2026 Progress and Announces Strategic Leadership Transitions Marking Next Era of Execution and Growth

August 11, 2026

Bicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8:30 AM ET

August 04, 2026

Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors

Top movers in Friday's after hours session ↗

July 31, 2026

Via Chartmill

July 28, 2026

Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

July 02, 2026

What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors? ↗

June 13, 2026

Bicara (BCAX) Q4 2025 Earnings Transcript ↗

June 01, 2026

Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer ↗

May 22, 2026

Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC

May 21, 2026

Bicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio Bet ↗

May 15, 2026

Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back ↗

May 15, 2026

Bicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal Data ↗

May 14, 2026

Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

May 13, 2026

Bicara (BCAX) Q1 2026 Earnings Transcript ↗

May 11, 2026

Bicara Therapeutics Q1 Earnings Call Highlights ↗

May 11, 2026

Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

May 11, 2026

Bicara Therapeutics Chief Medical Officer Sells 5,500 Shares for $126,000 ↗

May 04, 2026

Bicara Therapeutics to Report First Quarter 2026 Financial Results and Business Updates on May 11, 2026, at 8:30 AM ET

May 04, 2026

Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

April 03, 2026